Thermo Fisher Scientific has signed an agreement for the acquisition of Sanofi’s steriles manufacturing site located in Ridgefield in the US state of New Jersey for an undisclosed sum.
This is an expansion of the company’s partnership with Sanofi and is aimed at enhancing drug product manufacturing in the US.
Go deeper with GlobalData
The Ridgefield site will continue to produce a range of therapies for Sanofi while expanding its capacity to meet increasing demands from other pharmaceutical and biotech firms.
It is an advanced sterile fill-finish and packaging site supported by more than 200 employees.
Thermo Fisher chairman, president and CEO Marc Casper stated: “Sanofi’s Ridgefield site will strengthen our US manufacturing capabilities, enabling us to better support our pharmaceutical and biotech customers with the critical production capacity needed for essential medicines.
“We will also expand and further strengthen our long-standing partnership with Sanofi, while investing to bring additional capacity and enhanced capabilities at this site. We look forward to welcoming all Ridgefield employees to Thermo Fisher later this year.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThermo Fisher’s global sterile fill-finish manufacturing network already includes US locations in Greenville, North Carolina and Plainville, Massachusetts.
These sites form part of the company’s Accelerator Drug Development 360° contract development and manufacturing organisation (CDMO) and contract research organisation (CRO) solutions, reforming the pharmaceutical value chain for biopharma and biotech companies to accelerate the delivery of key medicines to patients.
The transaction between Thermo Fisher and Sanofi is subject to standard closing conditions and scheduled for completion in the second quarter (Q2) of 2025.
The plant will be incorporated into Thermo Fisher’s pharma services business within its laboratory products and biopharma services segment.
Sanofi manufacturing and supply global head Brendan O’Callaghan stated: “This expansion of our long-term partnership with Thermo Fisher will help ensure a continued supply of high-quality Sanofi products, maintaining our commitment to American manufacturing and supporting our customers and patients in the US, while enabling the future development and growth of the site.”
In June 2025, Thermo Fisher and Ethris partnered to deliver a fully integrated messenger ribonucleic acid (mRNA) solution for biopharmaceutical developers.
